I agree with your post SC.
The reason for the cost of product is that the TRIPP study is funded by the company, as is the percutaneous study so those treatments don't earn revenue. I kinda hope they can recoup that in the R&D reimbursement
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-20
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$1.08 |
Change
-0.050(4.42%) |
Mkt cap ! $20.33M | |||
| Open | High | Low | Value | Volume |
| $1.15 | $1.15 | $1.08 | $45.62K | 40.76K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 718 | $1.08 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.10 | 2361 | 1 |
View Market Depth
| Last trade - 16.10pm 30/07/2025 (20 minute delay) ? |
| OSL (ASX) Chart |